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Abstract: Several biologically relevant phospholipids were assessed as potential 
carriers/additives for rapidly dissolving solid formulations of piroxicam (Biopharmaceutics 
Classification System Class II drug). On the basis of in vitro dissolution studies, 
dimyristoylphosphatidylglycerol (DMPG) was ranked as the first potent dissolution rate 
enhancer for the model drug. Subsequently, the solid dispersions of varying 
piroxicam/DMPG ratios were prepared and further investigated. Within the concentration 
range studied (6.4-16.7 wt %), the dissolution rate of piroxicam from the solid dispersions 
appeared to increase as a function of the carrier weight fraction, whereas the cumulative 
drug concentration was not significantly affected by piroxicam/DMPG ratio, presumably 
due to a unique phase behavior of the aqueous dispersions of this carrier phospholipid. 
Solid state analysis of DMPG-based formulations reveled that they are two-component 
systems, with a less thermodynamically stable form of piroxicam (Form II) being dispersed 
within the carrier. Finally, oral bioavailability of piroxicam from the DMPG-based 
formulations in rats was found to be superior to that of the control, as indicated by the 
bioavailability parameters, cmax and especially Tmax (53 g/mL within 2 h vs. 39 g/mL 
within 5.5 h, respectively). Hence, DMPG was regarded as the most promising carrier 
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phospholipid for enhancing oral bioavailability of piroxicam and potentially other Class II 
drugs. 
Keywords: poorly water soluble drugs; phospholipids; solid dispersions; dissolution; 
bioavailability 
 
1. Introduction 
Sufficient aqueous solubility is a prerequisite for effective oral delivery of any therapeutic agent. 
However, low soluble and highly permeable drug molecules are gradually becoming prevailing in the 
development pipelines of pharmaceutical companies. Such drug molecules fall into Biopharmaceutics 
Classification System (BCS) Class II [1], for which the dissolution is usually the rate-limiting step for 
gastrointestinal absorption. To enhance dissolution rate and thus oral absorption of the Class II drugs 
numerous formulation strategies have been developed. These encompass salt formation [2], micro- and 
nanosizing [3], and solid dispersions [4-6], to name a few. The latter approach is recently regaining 
interest within the pharmaceutical industry, especially in the context of amorphous and nanoparticulate 
formulations [7-10]. 
Traditionally, freely water-soluble polymers such as high molecular weight polyethylene glycols 
(PEG) and polyvinylpyrrolidones (PVP) have been utilized as carriers for solid dispersion 
formulations [11,12]. However, the literature search has revealed that lipid-based systems 
demonstrated a higher success rate in enhancing the bioavailability of Class II drugs [1,5]. 
Phospholipids are the most promising group of carriers that has been probed for lipid-based 
formulations [13-15]. Phospholipids are amphiphilic compounds and, when equilibrated with excess 
water, spontaneously form bilayer structures (liposomes) having the capacity to entrap drug solutes. 
The drug partitioned in these bilayer structures of high surface area is transported to the stationary or 
diffusion layer yielding an increased rate of dissolution into aqueous environment [16]. Moreover, the 
use of lipids and lipid-like compounds as drug carriers is thought to promote oral absorption via 
intrinsic lipid pathways [5]. Finally, the severity of some adverse effects – for instance, the 
gastrointestinal tract ulceration and bleeding associated with non-steroidal anti-inflammatory drugs 
(NSAIDs) - can be reduced through lipid-based formulations [16,17]. 
Piroxicam is an NSAID that belongs to the BCS Class II drugs and thus its oral absorption is 
considered to be dissolution-rate limited [1,18]. In fact, several studies have reported a significant 
increase in the dissolution rate of piroxicam solid dispersions over the pure drug formulations [19-21]. 
In these systems, mainly PEG and PVP have been used as drug carriers and only the recent study [22] 
has exploited in vitro dissolution and permeability of phospholipid-based solid dispersions. 
Nevertheless, the in vivo performance of lipid-based formulations of piroxicam has not received much 
attention in the literature. 
Hence, the present study was designed to compare the pharmacokinetic properties of piroxicam 
delivered as pure drug and phospholipid-based solid dispersions and thus evaluate the potential  
of these delivery systems for oral bioavailability enhancement of the model drug. Several  
biologically relevant phospholipids (dimyristoylphosphatidylglycerol, dimyristoylphosphatidylcholine, 
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dipalmitoylphosphatidylcholine, and distearoylphosphatidylcholine) were initially selected as drug 
carriers for solid dispersion formulations and probed in vitro. The most potent phospholipid 
(dimyristoylphosphatidylglycerol) —in terms of dissolution rate enhancement—was then used as the 
carrier for formulation optimization and in vivo assessment. In addition, solid-state properties of the 
phospholipid-based formulations were studied to gain a better understanding of the relationship 
between the drug physical state and formulation performance. 
2. Experimental Section 
2.1. Materials 
Piroxicam, dimyristoylphosphatidylglycerol (DMPG), dimyristoylphosphatidylcholine (DMPC), 
dipalmitoylphosphatidylcholine (DPPC), and distearoylphosphatidylcholine (DSPC) were purchased 
from Sigma Chemicals (St. Louis, MO) and were used as received. The HPLC grade solvents used 
throughout the study were obtained from Fisher Scientific. 
2.2. Preparation of Phospholipid-Based Solid Dispersions and Physical Mixture 
Solid dispersions of piroxicam and phospholipids were prepared by a solvent method. Specifically, 
piroxicam and required amount of a phospholipid (DMPC, DMPG, DPPC or DSPC) were 
subsequently dissolved in chloroform with gentle stirring. Chloroform was removed at room 
temperature under nitrogen and the solids were dried in a vacuum desiccator overnight. Solid 
dispersions were tested within 48 hours after preparation. Control piroxicam was prepared in the same 
manner with no phospholipid added. Physical mixtures were prepared by gently triturating appropriate 
quantities of piroxicam and a phospholipid. 
2.3. Dissolution Studies 
Prior to dissolution studies, the samples were passed through an 80-mesh sieve. The dissolution 
studies were performed using VK7000 dissolution test apparatus with an external temperature control 
unit and VK8000 automatic sample collector (VanKel Industries, Inc. Edison, NJ). An USP standard 
paddle continuously stirred the dissolution medium (900 mL of distilled deionized water maintained at 
37 ºC) at 100 rpm. The powders (containing 20 mg of piroxicam) were sprinkled on the surface of the 
stirred dissolution medium at the beginning of the study (time zero). Solid dispersion powders 
dispersed quickly and distributed homogeneously with the stirring. At designated time intervals, 
samples were taken by the automatic sample collector and the concentration of piroxicam dissolved 
was determined using a UV spectrophotometer at wavelength 360 nm (Spectronic 1201, Milton Roy), 
where no interference with the carrier phospholipids was observed. The initial dissolution rate was 
calculated over the first 5 min of the test. 
2.4. Differential Scanning Calorimetry (DSC) 
Differential scanning calorimetry curves were obtained with a Differential Scanning Calorimeter 
2010 (TA Instruments, Inc. New Castle, DE). About 2-4 mg of sample was loaded into an aluminum 
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sample pan for each run. The thermal cycle was performed using a 10 ºC/min heating rate under an 
argon atmosphere from 25 to 300 ºC. The temperature and enthalpy of the signal were calibrated using 
the melting transition of indium (Tm = 156.6 ºC). 
2.5. Powder X-ray Diffraction (PXRD) 
Powder X-ray diffraction studies were done with a XDS2000 automated powder diffractometer 
(SCINTAG, CA). About 50 mg of each sample was run as a smear mount on a glass slide. X-ray 
diffraction patterns were obtained by using Cu-K radiation ( = 1.54060 angstroms), 40 kV, 30 mA, 
0.03 degrees/step and 1 degree 2-theta/min. 
2.6. Bioavailability Studies 
The oral absorption of piroxicam was determined in male Sprague-Dawley rats (weight 270-340 g). 
The external jugular vein of rats was cannulated. Animals were housed in individual cages, and given 
free access to food and water. One day after surgery, rats (n = 3) were given 20 mg/kg equivalent of 
piroxicam by oral administration. The vehicle was 1.0% hydroxypropylmethyl cellulose. Blood 
samples were drawn over 48 hours through the jugular vein and collected in Microtainer brand tube 
with lithium heparin. Samples were centrifuged immediately and the supernatant plasma was separated 
and stored at -70 ºC until analysis. Pharmacokinetic parameters were calculated using the computer 
program LAGRAN [23]. Differences in the pharmacokinetic parameters obtained between two groups 
were statistically evaluated using Student's unpaired t-test (p = 0.05). 
2.7. HPLC Analysis 
Plasma piroxicam concentrations were determined by a modified HPLC method [24]. Calibration 
samples were prepared by making the appropriate dilution of stock solution of piroxicam (1 mg/mL in 
0.04 M phosphate buffer pH 8.0) in drug free rat plasma. Samples of plasma (0.1 mL) were placed in  
20 mm × 150 mm glass culture tubes with screw caps; 50 L of internal standard (Naproxen,  
0.1 mg/mL in 0.04 M phosphate buffer pH 8.0), 0.2 mL of 1.0 M phosphate buffer (pH 2.0) and 5 mL 
of methylene chloride were added. The tubes were capped and shaken for 10 minutes and then 
centrifuged at 2000 ×g for 10 minutes. The aqueous layer was aspirated and the organic layer was 
dried under nitrogen. Samples were reconstituted with 0.1 mL mobile phase. Chromatographic 
separation was done on a Waters Bondapak (C18, 3.9 × 300 mm) column with a C18 precolumn 
insert. The mobile phase was 45% methanol in phosphate buffer (pH 8.0) and the flow rate was  
1.0 mL/min. The UV detector (Waters 486) was set at 330 nm. An aliquot of 50 L of the reconstituted 
solution was injected onto the HPLC column. The sensitivity of the method was about 50 g/mL. 
3. Results and Discussion 
3.1. Effect of the Carrier Phospholipid on Dissolution Rate of Piroxicam 
In order to identify the most potent dissolution rate enhancer for the model drug, the 10:1 (drug-to-
carrier ratio, w/w) binary solid dispersions of piroxicam with varying carrier phospholipids such as 
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DMPC, DMPG, DPPC and DSPC were initially prepared and subsequently evaluated in terms of their 
dissolution performance. The data presented in Figure 1 clearly show that regardless of the carrier, the 
dissolution rate of the drug from the solid dispersions was significantly (up to a 17-fold) higher when 
compared to that of control piroxicam. Further, an analysis of the initial dissolution rates and limiting 
concentrations after 60 min yielded by the different solid dispersions (Table 1) was performed. This 
analysis made it possible to establish a rank order—DSPC< DPPC< DMPC<DMPG—of the carrier 
phospholipids with respect to their enhancing effect on the dissolution rate of piroxicam. 
Figure 1. Dissolution profiles of the 10:1 (drug-to-carrier ratio) solid dispersions of 
piroxicam with various phospholipids in comparison with control piroxicam at 37 ºC in 
distilled water. Each data point refers to mean ± SD (n = 3). 
 
 
It is worth noting that the established rank order correlated well with the main phase transition 
temperature (Tc) of the carrier phospholipids. More specifically, DPPC and DSPC as phospholipids 
with Tc higher than 37 ºC [25] (i.e. the temperature of the dissolution medium) caused the minimal 
effect on the dissolution rate of piroxicam. Obviously, this can be attributed to the fact that under the 
present experimental conditions these phospholipids remained predominantly in the solid crystalline 
state. In contrast, DMPC and DMPG, the phospholipids with Tc lower than 37 ºC [26], did undergo the 
phase transition at the experimental temperature and thus demonstrated the utmost enhancing effect on 
the dissolution kinetics of the model drug. 
Hence, DMPG appeared to be the most promising carrier phospholipid for solid dispersion 
formulations of piroxicam and was selected for further investigations. 
Table 1. Dissolution characteristics of different solid dispersions of piroxicam (drug and 
phospholipid weight ratio 10:1) and piroxicam alone (mean ± SD, n  3). 
Composition 
 
Initial Dissolution Rate 
(% released/min) 
% Released after 60 min  
Control 0.4 ± 0.2 19.7 ± 4.6 
Piroxicam-DMPG 6.7 ± 1.5 76.1 ± 4.1  
Piroxicam-DMPC 4.9 ± 0.8 54.2 ± 11.5 
Piroxicam-DPPC 4.1 ± 1.0 46.8 ± 5.1 
Piroxicam-DSPC 3.1 ± 0.7 43.8 ± 4.0 
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3.2. Effect of DMPG Weight Fraction on the Dissolution Rate of Piroxicam 
It is generally known that the dissolution rate of a drug may increase as a function of the carrier 
concentration in the solid dispersion [13,15,19]. Thus, to evaluate the effect of DMPG weight fraction 
on the dissolution rate of piroxicam, the solid dispersions with varying drug-to-carrier ratios (5:1, 10:1, 
and 15:1) were prepared and tested. 
The dissolution parameters of piroxicam as a function of the weight fraction of DMPG in these 
systems are plotted in Figure 2. These results revealed that although increasing the DMPG weight 
fraction in the solid dispersions from 6.4 to 16.7% (15:1 to 5:1) resulted in about 53% gain (from 4.9 
to 7.5% released/min) in the initial dissolution rate, it had no significant (~ 5% greater) effect on the 
cumulative amount of piroxicam dissolved in 60 min from these systems. Such dissolution 
performance of DMPG-based solid dispersions is likely to be associated with a unique phase behavior 
of this phospholipid in diluted aqueous dispersions. Under these conditions, DMPG has been shown to 
undergo a sharp phase transition (instead of the chain melting process), with Tc being increased up to 
about 41 ºC with decrease in the phospholipid concentration [26]. Dissolution studies were apparently 
performed under the analogous conditions, where DMPG exhibited an elevated Tc similar for all the 
solid dispersion systems studied. As a result, the hydration of the carrier phospholipid was retarded so 
that no considerable difference among the formulations in terms of the cumulative amount of the drug 
dissolved was observed. 
For comparison, the dissolution test was also performed with the 15:1 piroxicam-DMPG physical 
mixture. As expected, the physical mixture was found to exhibit a slightly enhanced dissolution profile 
when compared to that of the control. Specifically, an increase in both initial dissolution rate (about a 
2-fold) and the drug limiting concentration after 60 min (by ~ 45%) was observed. This enhancing 
effect is commonly attributed to improved wetting properties of poorly water soluble drugs in the 
presence of wetting agents such as phospholipids and liposome formation in the dissolution media [5]. 
Figure 2. Effect of DMPG weight fraction on the dissolution parameters of piroxicam from 
solid dispersions at 37 ºC in distilled water. 
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3.3. Solid-state Characterization of DMPG-based Solid Dispersions 
Rearrangement of the crystal structure or complete loss of the long-range order (amorphization), or 
the formation of solid solutions or eutectics are among the common reasons that account for an 
increased dissolution rate of the APIs from solid dispersions [6]. Moreover, the model dug, piroxicam, 
is known to exhibit polymorphism [27,28] and is thus susceptible to various solid phase 
transformations during processing. Hence, to gain an insight into the mechanism of improved 
dissolution rate of piroxicam from DMPG solid dispersions, the solid-state properties of these systems 
were investigated by means of PXRD and DSC. 
Representative powder X-ray diffraction (PXRD) patterns for the starting materials, control, 
physical mixture, and solid dispersions of piroxicam and DMPG are shown in Figure 3. By comparing 
the theoretical [29,30] and experimental PXRD patterns (Figure 3A), untreated (commercial) 
piroxicam was identified as Form I (BIYSEH). The PXRD pattern of the physical mixture (Figure 3B) 
was found to be a simple summation of those of piroxicam (Form I) and DMPG. However, the PXRD 
patterns yielded by the solvent-treated samples, the control and solid dispersions (Figure 3B), did not 
match well with the diffraction patterns of either Form I or the piroxicam-DMPG physical mixture. 
This result indicates that a solution-mediated phase transformation occurred during the solid dispersion 
formation. In particular, the control was identified as a mixture of the two polymorphic forms, Form I 
and Form II (BIYSEH02). This finding is consistent with the previous studies [21,27] that reported the 
formation of polymorphic mixtures of piroxicam during solvent-based processes. In this context, it was 
interesting to note that the PXRD pattern of the solid dispersion was in a reasonable agreement with 
that of Form II. Obviously, this metastable form of piroxicam was formed as a result of enhanced 
crystallization kinetics due to the presence of a solubilizing agent (DMPG) in the media. Furthermore, 
piroxicam (Form II) exhibited no phase transformation within the formulation upon storage at ambient 
conditions for three months, as verified by PXRD analysis. Form II has been shown to have a faster 
dissolution rate as compared to Form I [27] and thus this solid phase transformation can be linked with 
the enhanced dissolution kinetics of the DMPG-based formulations. 
Thermal characteristics of untreated piroxicam, the control, physical mixture, and the solid 
dispersions are compared in Table 2. In accordance with PXRD results, untreated piroxicam showed a 
sharp endotherm at 201.1 ºC (onset temperature), which is consistent with the melting point of  
Form I [27]. Control piroxicam yielded a broader endotherm with the onset at around 199.3 ºC that 
corresponded to the melting point of Form II [27], further confirming the formation of a polymorphic 
mixture. With solid dispersions, a gradual depression in both the melting temperature and enthalpy of 
melting with the increase of DMPG weight fraction in the formulation was observed, signifying an 
increased fraction of the drug dissolved in the carrier phospholipid. It should be emphasized, however, 
that the 15:1 physical mixture of piroxicam (Form I) and DMPG also yielded a melting endotherm 
downshifted to 198.9 ºC. This implies that no conclusion regarding the polymorphic form of a drug 
dispersed in the carrier could be drawn solely based on the DSC analysis. Nevertheless, some 
correlation between the reduced melting point (and especially enthalpy of fusion) and increased initial 
dissolution rate of the formulations could be observed. 
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Table 2. Thermal characteristics of piroxicam and piroxicam-DMPG binary systems. Each 
point is the mean ± SD (n = 3). 
Sample 
 
Melting temperature 
(onset, ºC) 
Heat of melting 
(H, J/g) 
Commercial Piroxicam 201.1 ± 0.6 103.3 ± 1.0 
Control Piroxicam  199.3 ± 1.1 98.5 ± 1.8 
Piroxicam:DMPG physical mixture (15:1, w/w) 198.9 ± 1.6 93.7 ± 0.9 
Piroxicam:DMPG solid dispersions    
     15:1 (w/w) 198.4 ± 2.3 91.1 ± 1.9 
     10:1 (w/w) 196.8 ± 1.7 75.6 ± 2.5 
      5:1 (w/w) 195.2 ± 2.1 74.4 ± 3.2 
Figure 3. Powder X-ray diffraction patterns of (A) commercial piroxicam in comparison 
with theoretical patterns of its polymorphic forms, Form I (BIYSEH) and Form II 
(BIYSEH02), and (B) the carrier phospholipid DMPG, the 15:1 (w/w) piroxicam-DMPG 
physical mixture and solid dispersion vs. control piroxicam. 
3.4. In vivo Performance of 15:1 Piroxicam-DMPG solid Dispersion 
The preliminary in vitro studies revealed no significant positive effect of DMPG weight fraction on 
the dissolution rate of piroxicam (see Section 3.2). For this reason, the 15:1 piroxicam-DMPG solid 
dispersions (i.e., the formulations with the highest drug loading) were utilized for in vivo studies. 
The representative plasma piroxicam concentration vs. time profiles of the two oral formulations, 
the control and the 15:1 solid dispersion, after the single dose are plotted in Figure 4; the main 
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pharmacokinetic parameters for these formulations are summarized in Table 3. The analysis of the data 
shows that the piroxicam-DMPG solid dispersion exhibits a superior pharmacokinetic profile, reaching 
the peak plasma concentration (cmax) of about 53 g/mL rather fast (Tmax = 2 h). The concentration 
maximum of the control was about 39 g/mL and 1.4-fold lower than that of the solid dispersion 
formulation and was reached within a much longer period of time (approximately 5.5 h), indicating the 
differences in absorption properties (and thus bioavailability) of these piroxicam formulations. The 
other pharmacokinetic parameters, including AUC0-48, elimination half life and mean residence time 
(MRT), were comparable for both formulations. 
Therefore, referring to the dissolution behavior of these model systems, as described above, a 
correlation between in vitro dissolution and in vivo bioavailability of piroxicam can be found. In 
particular, the increased rate and extent of in vitro dissolution appeared to correlate with the enhanced 
bioavailability parameters such as cmax and Tmax. The enhanced human absorption of NSAIDs is 
usually associated with an improved analgesic effect [31]. In this context, piroxicam-DMPG solid 
dispersions are expected to exhibit a superior pharmacological effect. 
Figure 4. Representative plasma concentration-time profiles for two piroxicam 
formulations. The DMPG-based solid dispersion formulations of piroxicam were 
administered orally to rats and compared to the same dose of control piroxicam (20 
mg/kg). 
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Table 3. Pharmacokinetic parameters (mean ± SD, n = 3) of two piroxicam formulations 
following single-dose oral administration in rats. 
Parameters Formulation 
Control  DMPG-based solid dispersion  
(15:1, w/w)   
Peak plasma concentration (cmax, g/mL) 38.9 ±14.3 53.3 ± 15.1  
Time to peak concentration (Tmax, h) 5.5 ± 2.1 2.0 ± 0.0* 
AUC0-48 (g/mL . h) 921 ± 207 1210 ± 254 
Elimination half life (T1/2, h) 13.0 ± 2.7  14.5 ± 5.6 
Mean residence time (MRT, h) 25.9 ± 5.5 27.7 ± 8.2 
* Significantly different from control piroxicam (p < 0.05). 
4. Conclusions 
Four phospholipids, dimyristoylphosphatidylglycerol (DMPG), dimyristoylphosphatidylcholine 
(DMPC), dipalmitoylphosphatidylcholine (DPPC), and distearoylphosphatidylcholine (DSPC), were 
assessed as potential carriers/additives for rapidly dissolving solid formulations of piroxicam (BCS 
class II drug). Among these phospholipids, DMPG was shown to be the most potent dissolution rate 
enhancer for the model drug. However, due to a peculiar thermal behavior of DMPG in diluted 
aqueous dispersions, an extended study on the phospholipids concentration/dissolution rate 
relationships is recommended in order to rationally design a formulation. Furthermore, a correlation 
between the rate and extent of in vitro dissolution and the bioavailability parameters (cmax and Tmax) of 
piroxicam was demonstrated. Hence, DMPG-based formulations proved to be the most promising 
delivery systems for oral bioavailability enhancement of BCS Class II drugs such as piroxicam. 
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